Top Page
Calidi Biotherapeutics
(NYSE MKT:CLDI)
Calidi Biotherapeutics (CLDI) vs. S&P 500 (SPY)
Calidi Biotherapeutics Business Overview & Revenue Model
Calidi Biotherapeutics Financial Statement Overview
| Breakdown | ||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 45.00K | 449.00K | 0.00 | Gross Profit |
| -838.00K | -1.26M | -229.00K | 355.00K | 0.00 | EBIT |
| -25.29M | -28.99M | -23.13M | -1.78M | -6.77M | EBITDA |
| -17.32M | -27.58M | -25.00M | -9.45M | -6.65M | Net Income Common Stockholders |
| -17.07M | -29.22M | -25.43M | 3.39M | -7.94M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.24M | 2.05M | 472.00K | 1.06M | 420.00K | Total Assets |
| 7.41M | 10.02M | 2.60M | 231.77M | 1.85M | Total Debt |
| 11.71M | 7.24M | 5.99M | 5.18M | 11.72M | Net Debt |
| 10.47M | 5.19M | 5.52M | 4.12M | 11.30M | Total Liabilities |
| 21.98M | 18.25M | 43.44M | 16.45M | 24.33M | Stockholders Equity |
| -14.57M | -8.23M | -40.84M | 215.32M | -22.48M |
| Cash Flow | Free Cash Flow | |||
| -31.90M | -27.57M | -13.64M | -1.29M | -5.18M | Operating Cash Flow |
| -31.01M | -26.98M | -13.21M | -1.08M | -4.83M | Investing Cash Flow |
| -57.15K | -478.00K | -494.00K | -230.00M | -388.00K | Financing Cash Flow |
| 31.83M | 29.04M | 12.09M | 232.15M | 4.70M |
Calidi Biotherapeutics Technical Analysis
Calidi Biotherapeutics Risk Analysis
Calidi Biotherapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.20B | 3.26 | -40.34% | 2.93% | 17.68% | 1.94% | |
50 Neutral | $23.33M | ― | -111.19% | ― | 237.38% | 60.32% | |
44 Neutral | $13.84M | ― | -74.28% | ― | -2.36% | 9.68% | |
43 Neutral | $13.93M | ― | -81.92% | ― | -40.94% | 51.90% | |
38 Underperform | $8.73M | ― | -58.40% | ― | ― | 1.00% | |
37 Underperform | $15.75M | ― | 354.78% | ― | ― | 64.19% |
Calidi Biotherapeutics Corporate Events
On April 17, 2025, Allan Camaisa announced his resignation as CEO and Chairman of Calidi Biotherapeutics, effective April 21, 2025, while remaining a board member. Eric Poma, Ph.D., was appointed as the new CEO and Class I director, effective April 22, 2025. Poma brings over 30 years of experience in the biopharmaceutical industry, previously serving as CEO of Molecular Templates. His appointment is expected to drive Calidi’s clinical and preclinical programs forward, leveraging his expertise in oncology and capital fundraising. The transition is part of Calidi’s strategy to advance its virotherapy platform and clinical trials, aiming to enhance shareholder value and strengthen its market position.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Neutral.
Calidi Biotherapeutics faces substantial financial and technical challenges, with significant risks due to lack of revenue and profitability. However, recent corporate developments and strategic advancements in clinical programs offer some optimism for the future.
To see Spark’s full report on CLDI stock, click here.
On April 10, 2025, Calidi Biotherapeutics announced the appointment of Dr. Guy Travis Clifton as Chief Medical Officer, Consultant, and Advisor. Dr. Clifton, a seasoned surgical oncologist with extensive experience in drug development and cancer immunotherapy, will provide medical and scientific expertise to advance Calidi’s clinical programs. His appointment is expected to bolster the company’s efforts in developing its stem cell-based and enveloped virus platforms, potentially transforming cancer treatment.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics presents a high-risk investment with financial instability and technical weakness. While recent corporate developments offer some optimism, the company’s lack of revenue and profitability, combined with bearish technical indicators, weigh heavily on its overall stock score.
To see Spark’s full report on CLDI stock, click here.
Calidi Biotherapeutics reported its fourth quarter and full-year 2024 financial results, highlighting significant advancements in its clinical programs. The company demonstrated the ability of its CLD-400 platform to deliver gene therapy to tumors and filed an IND for a Phase 1 trial of CLD-201 for solid tumors in March 2025. Recruitment began for a Phase 1 trial of CLD-101 in high-grade glioma patients at Northwestern University, and 14 patients were enrolled in a City of Hope trial for recurrent high-grade glioma. Financially, Calidi reduced its net loss and expenses in 2024 compared to 2023, with increased cash reserves by year-end.
On March 10, 2025, Calidi Biotherapeutics announced promising preclinical results for its RTNova platform, which successfully delivered transient gene therapy payloads to tumors. The platform addresses challenges in treating advanced metastatic cancers by using a vaccinia virus strain enveloped with a human cell membrane to target distant tumors. This innovation has shown efficacy in altering the tumor microenvironment and eradicating certain tumors in preclinical models, potentially revolutionizing cancer treatment and opening opportunities for partnerships.
On January 28, 2025, Calidi Biotherapeutics announced the termination of its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, effective January 23, 2025. The decision followed a successful fundraising effort that bolstered its cash position to $9.6 million as of December 31, 2024, allowing the company to focus on its clinical and operational goals without the SEPA framework. This strategic move reflects Calidi’s commitment to enhancing shareholder value and advancing its leadership in targeted antitumor virotherapies, with recent progress including an IND clearance by the FDA and new funding from public offerings.